Birch pollen allergen-specific immunoglobulin E (Birch sIgE)

Birch pollen allergen-specific immunoglobulin E (IgE) is a specialized antibody produced by B cells in response to exposure to birch pollen proteins, primarily the major allergen Bet v 1 (UniProt P15494) [1]. In sensitized individuals, these IgE molecules circulate and bind to the high-affinity FceRI receptors on the surface of mast cells and basophils (StatPearls) [2]. When the individual is re-exposed to birch pollen, the allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators such as histamine, prostaglandins, and leukotrienes (PubMed) [3]. This physiological cascade results in the symptoms of seasonal allergic rhinitis, conjunctivitis, and potentially allergic asthma (NIH) [4]. Therapeutic interventions targeting this pathway include allergen immunotherapy (AIT), such as Itulazax, which utilizes standardized birch extracts to shift the immune response toward tolerance by inducing IgG4 blocking antibodies (EMA) [5]. Additionally, monoclonal antibodies like Omalizumab act by neutralizing free IgE, thereby preventing its interaction with cellular receptors and mitigating the allergic response (PubMed) [6]. Monitoring specific IgE levels is crucial for diagnosing sensitization and assessing the efficacy of these therapeutic approaches in clinical practice (Journal of Allergy and Clinical Immunology) [7].

Other names

Bet v 1-specific IgEBirch-specific IgEAnti-Bet v 1 IgEBetula verrucosa-specific IgE

Allergen immunotherapy (AIT) induces immune tolerance by promoting the production of IgG4 blocking antibodies and regulatory T cells, while anti-IgE biologics sequester free IgE to prevent its binding to high-affinity FceRI receptors on effector cells.